AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36129681 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography monitoring indicators (including respiratory variability of inferior vena cava diameter, tricuspid annular plane systolic excursion)
Number of subjects: 150
Study 36129688 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast, 30 mg, twice daily
Number of subjects: 70
Study 36129735 — intervention group
Group type: EXPERIMENTAL
Intervention: GCSWLI (gender- and culturally sensitive weight loss intervention) with mHealth support including tailored SMS, Fitbit Charge 2, and Fitbit Aria Smart Scale
Number of subjects: 18
Study 36129735 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of Fitbit technology
Number of subjects: 18
Study 36129735 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of smart scale
Number of subjects: 18
Study 36129839 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIP testing recommended after vignette presentation
Number of subjects: 528
Study 36129839 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIP testing preference after presenting CHIP-independent risks
Number of subjects: 528
Study 36129839 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIP testing preference after presenting CHIP-associated risks
Number of subjects: 528
Study 36129839 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for testing when offered a CHIP clinic
Number of subjects: 528
Study 36129839 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for testing when offered hypothetical CHIP treatment
Number of subjects: 528
Study 36129839 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire for CHIP testing among participants
Number of subjects: 528
Study 36129839 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety caused by learning about CHIP
Number of subjects: 528
Study 36129967 — intervention group
Group type: EXPERIMENTAL
Intervention: NJH395 (Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate)
Number of subjects: 18
Study 36130079 — intervention group
Group type: EXPERIMENTAL
Intervention: Occipital alpha relative power during eyes-closed states
Number of subjects: 26
Study 36130079 — intervention group
Group type: EXPERIMENTAL
Intervention: Occipital theta relative power during eyes-open states
Number of subjects: 26
Study 36130079 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal theta relative power during eyes-open states
Number of subjects: 26
Study 36130086 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception threshold tracking using electrical currents with different shapes, duration, and intensities applied by skin electrodes activating large and small fibers.
Number of subjects: 80
Study 36130137 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment, details on dosage and duration not available.
Number of subjects: 0
Study 36130137 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available.
Number of subjects: 0
Study 36130238 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable hemoglobinometer (HemoCue 301)
Number of subjects: 896
Study 36130238 — intervention group
Group type: COMPARATOR
Intervention: Automated hematology analyzers (AHA)
Number of subjects: 896
Study 36130327 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 vaccination
Number of subjects: 988
Study 36130401 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 391
Study 36130401 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 391
Study 36130401 — intervention group
Group type: EXPERIMENTAL
Intervention: Calprotectin
Number of subjects: 391
Study 36130401 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 391
Study 36130401 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP and IL-6 combination
Number of subjects: 391
Study 36130401 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP and IL-6 optimal cutoff values
Number of subjects: 391
Study 36130401 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP and PCT
Number of subjects: 391
Study 36130480 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fructose diet
Number of subjects: 0
Study 36130480 — intervention group
Group type: COMPARATOR
Intervention: High-glucose diet
Number of subjects: 0
Study 36130508 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 treatment
Number of subjects: 9
Study 36130508 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy donors
Number of subjects: 9
Study 36130693 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with doses of 60 to 72 Gy in 2 Gy fractions
Number of subjects: 205
Study 36130734 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 1193
Study 36130734 — intervention group
Group type: COMPARATOR
Intervention: Opioid antagonists
Number of subjects: 1193
Study 36130734 — intervention group
Group type: COMPARATOR
Intervention: Mood stabilisers
Number of subjects: 1193
Study 36130734 — intervention group
Group type: COMPARATOR
Intervention: Atypical antipsychotics
Number of subjects: 1193
Study 36130741 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of systematic testing at admission in the STEMI cohort
Number of subjects: 9218
Study 36130741 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of plan blanc concentrating resources in emergency activities in the STEMI cohort
Number of subjects: 9218
Study 36130741 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-wave period management times for stroke
Number of subjects: 9218
Study 36130741 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-wave period management times for STEMI
Number of subjects: 9218
Study 36130741 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in use of care during per-wave period for STEMI
Number of subjects: 9218
Study 36130741 — intervention group
Group type: EXPERIMENTAL
Intervention: Associations between reorganisations and stroke management times
Number of subjects: 9218
Study 36130748 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-Alone Left Atrial Appendage Occlusion (LAAO)
Number of subjects: 0
Study 36130762 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative MRI or CT imaging (timing not specified)
Number of subjects: 0
Study 36130762 — intervention group
Group type: COMPARATOR
Intervention: Delayed postoperative imaging (between 36 and 72 hours postoperatively)
Number of subjects: 0
Study 36131237 — intervention group
Group type: EXPERIMENTAL
Intervention: Language-supported group antenatal care (gANC)
Number of subjects: 44
Study 36131333 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention (ILS)
Number of subjects: 3147
Study 36131333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 3147
Study 36131333 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET)
Number of subjects: 3147
Study 36131349 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 71
Study 36131349 — intervention group
Group type: EXPERIMENTAL
Intervention: General floor treatment
Number of subjects: 71
Study 36131349 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU treatment
Number of subjects: 71
Study 36131349 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise capacity
Number of subjects: 71
Study 36131349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary impairment
Number of subjects: 71
Study 36131349 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID syndrome
Number of subjects: 71
Study 36131848 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) for 14 days, limiting food and beverages to a 10-h window.
Number of subjects: 39
Study 36131934 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T-cell therapy
Number of subjects: 133
Study 36133308 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,5-Anhydroglucitol (1,5-AG) levels
Number of subjects: 2970
Study 36133827 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription opioid misuse (POM)
Number of subjects: 951
Study 36133827 — intervention group
Group type: EXPERIMENTAL
Intervention: Overuse of opioids
Number of subjects: 951
Study 36133827 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of opioids for effects other than analgesia
Number of subjects: 951
Study 36133827 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal syndrome
Number of subjects: 951
Study 36133827 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving for opioids
Number of subjects: 951
Study 36133827 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with POM
Number of subjects: 951
Study 36133956 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise (watt-max test and four high-intensity intervals)
Number of subjects: 20
Study 36133956 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 20
Study 36134579 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Number of subjects: 3
Study 36134579 — intervention group
Group type: EXPERIMENTAL
Intervention: Adeno-associated virus-mediated restoration of cardiac SIRT3 expression
Number of subjects: 3
Study 36134579 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 3
Study 36134657 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week supervised aerobic training intervention
Number of subjects: 21
Study 36135045 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib plus capecitabine (enrolled in NRDL)
Number of subjects: 0
Study 36135045 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib plus capecitabine (not enrolled in NRDL)
Number of subjects: 0
Study 36135045 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib plus capecitabine
Number of subjects: 0
Study 36135453 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary endarterectomy (PEA)
Number of subjects: 160
Study 36135453 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon pulmonary angioplasty (BPA)
Number of subjects: 160
Study 36135453 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 160
Study 36136180 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-guided buccal cortical plate separation
Number of subjects: 10
Study 36136178 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-type single-balloon enteroscopy (short SBE)
Number of subjects: 37
Study 36136274 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide depot
Number of subjects: 99
Study 36136294 — intervention group
Group type: EXPERIMENTAL
Intervention: Socazolimab (5 mg/kg)
Number of subjects: 104
Study 36136377 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Imagery (8-weekly, individual sessions)
Number of subjects: 60
Study 36136377 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Listening (independent music listening)
Number of subjects: 60
Study 36136377 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 60
Study 36136523 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (≤20 U/kg, max. 500 U per injection cycle for ≤6 injection cycles for spasticity; 20-75 U per injection cycle for ≤4 injection cycles for sialorrhea)
Number of subjects: 1159
Study 36136794 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in the therapist
Number of subjects: 587
Study 36136794 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in the treatment
Number of subjects: 587
Study 36136804 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI)
Number of subjects: 0
Study 36136804 — intervention group
Group type: COMPARATOR
Intervention: Intact cognition (noMCI)
Number of subjects: 0
Study 36136811 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable urine-TFV
Number of subjects: 198
Study 36136811 — intervention group
Group type: EXPERIMENTAL
Intervention: Undetectable urine-TFV
Number of subjects: 198
Study 36136994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac surgeries associated with diabetes, smoking, and elderly age in winter
Number of subjects: 9838
Study 36136994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac surgeries in elderly patients without diabetes and smoking
Number of subjects: 9838
Study 36136994 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant occurrence of diabetes and smoking
Number of subjects: 9838
Study 36136994 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous presence of older age and diabetes or smoking
Number of subjects: 9838
Study 36137526 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroShunt implantation with adjunctive use of mitomycin C (0.2-0.4 mg/mL applied for 2-3 min)
Number of subjects: 61
Study 36137526 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroShunt implantation
Number of subjects: 61
Study 36137583 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana smoking
Number of subjects: 0
Study 36137583 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-marijuana smokers)
Number of subjects: 0
Study 36137639 — intervention group
Group type: EXPERIMENTAL
Intervention: ChemoFit intervention (home-based physical activity and exercise intervention involving cardiovascular and strength exercise using resistance bands and pedometers)
Number of subjects: 22
Study 36137639 — intervention group
Group type: EXPERIMENTAL
Intervention: ChemoFit intervention
Number of subjects: 22
Study 36137658 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-inflow time arterial spin-labeling
Number of subjects: 44
Study 36137674 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) treatment
Number of subjects: 557
Study 36137711 — intervention group
Group type: EXPERIMENTAL
Intervention: VS-guided ablation using a contact force-sensing catheter
Number of subjects: 283
Study 36137735 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg two times per day
Number of subjects: 4362
Study 36137735 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg two times per day
Number of subjects: 4362
Study 36137735 — intervention group
Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 4362
Study 36137752 — intervention group
Group type: EXPERIMENTAL
Intervention: MICs infusion before kidney transplantation
Number of subjects: 10
Study 36137752 — intervention group
Group type: EXPERIMENTAL
Intervention: MICs infusion (highest dose) 7 days before surgery
Number of subjects: 10
Study 36137752 — intervention group
Group type: EXPERIMENTAL
Intervention: MICs infusion (highest dose)
Number of subjects: 10
Study 36137752 — intervention group
Group type: EXPERIMENTAL
Intervention: MICs infusion
Number of subjects: 10
Study 36138060 — intervention group
Group type: EXPERIMENTAL
Intervention: First visit behaviors
Number of subjects: 277
Study 36138060 — intervention group
Group type: EXPERIMENTAL
Intervention: Second visit behaviors
Number of subjects: 277
Study 36138060 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 risk perception
Number of subjects: 277
Study 36138060 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong behavioral changes at first visit
Number of subjects: 277
Study 36138138 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomass fuel use
Number of subjects: 497
Study 36138138 — intervention group
Group type: COMPARATOR
Intervention: Liquified petroleum gas (LPG)
Number of subjects: 497
Study 36138152 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel)
Number of subjects: 418
Study 36138152 — intervention group
Group type: COMPARATOR
Intervention: Tisagenlecleucel (tisa-cel)
Number of subjects: 418
Study 36138330 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-F scale
Number of subjects: 0
Study 36138362 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with immunotherapy
Number of subjects: 770
Study 36138362 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without immunotherapy
Number of subjects: 770
Study 36138362 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and radiotherapy
Number of subjects: 770
Study 36138362 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 770
Study 36138362 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 770
Study 36138362 — intervention group
Group type: EXPERIMENTAL
Intervention: LELC
Number of subjects: 770
Study 36138362 — intervention group
Group type: COMPARATOR
Intervention: LELC vs. NPC
Number of subjects: 770
Study 36138368 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding for at least 6 months
Number of subjects: 5249
Study 36138368 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding exclusively for at least 6 months
Number of subjects: 5249
Study 36138368 — intervention group
Group type: EXPERIMENTAL
Intervention: Not smoking in the month prior to delivery
Number of subjects: 5249
Study 36138368 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a Master's degree or higher
Number of subjects: 5249
Study 36138368 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a planned pregnancy
Number of subjects: 5249
Study 36138368 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 5249
Study 36138368 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower BMI
Number of subjects: 5249
Study 36138368 — intervention group
Group type: EXPERIMENTAL
Intervention: Less anxiety measured during pregnancy
Number of subjects: 5249
Study 36138368 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic women
Number of subjects: 5249
Study 36138368 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic Black women
Number of subjects: 5249
Study 36138689 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised intervention (details not specified)
Number of subjects: 0
Study 36138689 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 0
Study 36139154 — intervention group
Group type: EXPERIMENTAL
Intervention: PLK-cleaved LAP-TGF-β
Number of subjects: 34
Study 36139632 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 43
Study 36139910 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.5 g mixture of trehalose, spermidine, nicotinamide, and polyphenols
Number of subjects: 20
Study 36139910 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 20
Study 36143102 — intervention group
Group type: EXPERIMENTAL
Intervention: Single antiplatelets (SAPT)
Number of subjects: 80426
Study 36143102 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelets (DAPT)
Number of subjects: 80426
Study 36143102 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-K antagonists (VKA)
Number of subjects: 80426
Study 36143102 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC)
Number of subjects: 80426
Study 36143102 — intervention group
Group type: EXPERIMENTAL
Intervention: Both antiplatelets and oral anticoagulation
Number of subjects: 80426
Study 36143102 — intervention group
Group type: EXPERIMENTAL
Intervention: No antithrombotic therapy
Number of subjects: 80426
Study 36143388 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous amnioinfusion with Amnion Flush Solution (up to 100 mL/h, 2400 mL/day)
Number of subjects: 68
Study 36143388 — intervention group
Group type: COMPARATOR
Intervention: Standard PPROM therapy (antibiotics and corticosteroids)
Number of subjects: 68
Study 36144220 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning predictive algorithm (boosted ensemble algorithm XGBoost)
Number of subjects: 958
Study 36146760 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs)
Number of subjects: 89
Study 36146847 — intervention group
Group type: EXPERIMENTAL
Intervention: N-based ELISA test system
Number of subjects: 0
Study 36146847 — intervention group
Group type: COMPARATOR
Intervention: RBD-based serology tests
Number of subjects: 0
Study 36146847 — intervention group
Group type: EXPERIMENTAL
Intervention: N-based test systems
Number of subjects: 0
Study 36147300 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins A, β-carotene, and pantothenic acid measured in human milk samples
Number of subjects: 147
Study 36147777 — intervention group
Group type: EXPERIMENTAL
Intervention: Old fibroadipogenic progenitors
Number of subjects: 0
Study 36147777 — intervention group
Group type: COMPARATOR
Intervention: Young mice
Number of subjects: 0
Study 36147862 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NI)
Number of subjects: 0
Study 36147862 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy (NC)
Number of subjects: 0
Study 36147862 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 36148206 — intervention group
Group type: EXPERIMENTAL
Intervention: ONC201
Number of subjects: 3
Study 36148253 — intervention group
Group type: EXPERIMENTAL
Intervention: Current or ex-smokers (23 of 82 CS cases, 28.0%)
Number of subjects: 87
Study 36148253 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmokers
Number of subjects: 87
Study 36148362 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived partner support
Number of subjects: 152
Study 36148362 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based interventions
Number of subjects: 152
Study 36148649 — intervention group
Group type: EXPERIMENTAL
Intervention: PPG-based algorithm for detecting undiagnosed AF using wearable Fitbit devices.
Number of subjects: 455699
Study 36148691 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported computerized history taking (CHT) programme Clinical Expert Operating System (CLEOS)
Number of subjects: 54
Study 36148823 — intervention group
Group type: COMPARATOR
Intervention: Resting state EEG functional connectivity in theta band
Number of subjects: 180
Study 36148823 — intervention group
Group type: COMPARATOR
Intervention: Resting state EEG functional connectivity in beta band
Number of subjects: 180
Study 36148823 — intervention group
Group type: COMPARATOR
Intervention: Cortical functional connectivity in painful DPN patients
Number of subjects: 180
Study 36148823 — intervention group
Group type: COMPARATOR
Intervention: Individual significant functional connections in all frequency bands
Number of subjects: 180
Study 36148886 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation in the morning (06.00-10.00 am)
Number of subjects: 56
Study 36148886 — intervention group
Group type: COMPARATOR
Intervention: Irradiation in the afternoon (04.00-06.00 pm)
Number of subjects: 56
Study 36148886 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial haemoglobin (Hb) level
Number of subjects: 56